-- Now offering Cytiva Diagnostic Services, new diagnostic test development and 
support service virtually or at new lab, for point-of-care diagnostic 
developers to increase speed to market of new tests. 

-- Supply chain enhancements include increasing inventory, investing in plants 
and expanding number of partner organizations.

Cytiva launches new services ( 
https://c212.net/c/link/?t=0&l=en&o=2956937-1&h=4156851996&u=https%3A%2F%2Fwww.cytivalifesciences.com%2Fen%2Fus%2Fsolutions%2Flab-filtration%2Findustry%2Fdiagnostics%2Fcytivadiagnosticservices&a=new+services 
) for diagnostic developers and will establish new labs to meet the future 
needs of the industry ( 
https://c212.net/c/link/?t=0&l=en&o=2956937-1&h=2644493890&u=https%3A%2F%2Fwww.technologynetworks.com%2Fdiagnostics%2Farticles%2Fvital-lessons-for-the-diagnostics-industry-from-covid-19-338075&a=future+needs+of+the+industry 
). Cytiva Diagnostic Services will help developers bring point-of-care 
diagnostic tests to market quicker through infrastructure, expertise and 
consultation for point of care immunoassay development. A multi-million dollar 
investment will be used partly to expand chemistry labs in Cardiff, Wales as 
well as establishing design labs in Germany and China.

Cytiva has had a critical role working with diagnostic developers during the 
COVID-19 pandemic. In total, over 50 million people have been PCR tested using 
components or services from Cytiva. Diagnostic components, such as 
nitrocellulose membranes, are used in 18 immunoassay-based COVID-19 tests 
available today.

Investment in its molecular diagnostic component lab in Wales means more work 
with companies such as genedrive ( 
https://c212.net/c/link/?t=0&l=en&o=2956937-1&h=4109147890&u=http%3A%2F%2Fwww.genedriveplc.com%2Fpress-releases%2Fgdr_-_covid_update_(22.05.20).pdf&a=genedrive 
), a molecular diagnostics company. David Budd, CEO genedrive says, "Our R&D 
teams worked effectively together in combining their expertise, experience, and 
technologies to deliver innovative PCR Kits based on Cytiva's 'Ready-to-Go' 
formulations. The speed at which we were able to move together was facilitated 
by many previous years of cooperative working."

The new services will follow the same collaborative approach as Cytiva's work 
with Avacta ( 
https://c212.net/c/link/?t=0&l=en&o=2956937-1&h=1524375001&u=https%3A%2F%2Favacta.com%2Fupdate-on-covid-19-rapid-antigen-test-development-partnership-with-cytiva%2F&a=Avacta 
). The companies are co-developing a rapid antigen test strip for COVID-19 to 
provide a result in minutes using patient saliva.

Alastair Smith, CEO of Avacta, comments: "Cytiva has been a key partner in 
developing a rapid coronavirus antigen test and we continue to work closely 
with them, and our manufacturing partners, to finalise the test in a format 
suitable for massively scaled-up manufacturing processes to meet the 
anticipated demand."

The new services will include training, test optimization expertise and 
contract development and can be hosted virtually or in person at Cytiva's new 
lab in Dassel, Germany. Another lab for diagnostics development work is being 
planned for China in 2021. These projects form part of Cytiva's 500 million USD 
investment over five years ( 
https://c212.net/c/link/?t=0&l=en&o=2956937-1&h=4201436511&u=https%3A%2F%2Fwww.cytivalifesciences.com%2Fen%2Fus%2Fnews-center%2F5-years-500-million-usd-and-nearly-1000-people-cytiva-invests-for-global-capacity-expansion-10001&a=500+million+USD+investment+over+five+years 
) to expand manufacturing capacity.

Emmanuel Abate, Vice President, Genomics and Cellular Research at Cytiva, says: 
"We have seen a lot of new companies entering the field this year to address 
the challenges of the pandemic. As a diagnostic component provider with over 30 
years' experience, we have a key role supporting the industry through the next 
series of challenges with our manufacturing and design expertise."

Join Cytiva's Diagnostics Virtual Summit
On Oct 28 Cytiva is hosting a thought-provoking and interactive virtual summit 
showcasing recently launched technologies, products and solutions supporting 
the development of diagnostics. Register here ( 
https://c212.net/c/link/?t=0&l=en&o=2956937-1&h=1837712100&u=https%3A%2F%2Fwww.linkedin.com%2Fleap%2Fr%3Fcode%3DdHjVa5u%26lipi%3Durn%253Ali%253Apage%253Ad_flagship3_profile_view_base_recent_activity_details_shares%253Bu3TZGzdfQdWqNV1XgfglqA%253D%253D%26licu%3Durn%253Ali%253Acontrol%253Ad_flagship3_profile_view_base_recent_activity_details_shares-update_article_image&a=here 
) for the live event or access the playback (available for 12 months).

About Cytiva
Cytiva is a global life sciences leader with more than 7,000 associates across 
40 countries dedicated to advancing and accelerating therapeutics. As a trusted 
partner to customers that range in scale and scope, Cytiva brings speed, 
efficiency and capacity to research and manufacturing workflows, enabling the 
development, manufacture and delivery of transformative medicines to patients.

SOURCE: Cytiva